PMID- 28273997
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240328
IS  - 2249-782X (Print)
IS  - 0973-709X (Electronic)
IS  - 0973-709X (Linking)
VI  - 11
IP  - 1
DP  - 2017 Jan
TI  - Teneligliptin in Management of Diabetic Kidney Disease: A Review of Place in 
      Therapy.
PG  - OE05-OE09
LID - 10.7860/JCDR/2017/25060.9228 [doi]
AB  - Diabetes is a global health emergency of this century. Diabetic nephropathy is 
      the most common microvascular complication associated with Type 2 Diabetes 
      Mellitus (T2DM). T2DM has been reported as a major etiological factor in almost 
      45% of patients undergoing dialysis due to kidney failure. Lifestyle 
      modifications; cessation of smoking, optimum control of blood glucose, blood 
      pressure and lipids are required to reduce the progression of Diabetic Kidney 
      Disease (DKD). Presently, Dipeptidyl peptidase-4 (DPP-4) inhibitors are preferred 
      in the management of T2DM due to their established efficacy; favorable 
      tolerability including, low risk of hypoglycaemia; weight neutrality and 
      convenient once-a-day dosage. Present evidence suggests that linagliptin and 
      teneligliptin can be used safely without dose adjustments in patients with T2DM 
      with renal impairment, including End Stage Renal Disease (ESRD). There is a 
      limited data about teneligliptin particularly in T2DM patients with renal 
      impairment. The objective of this review is to evaluate efficacy and safety of 
      teneligliptin in T2DM patients with renal impairment, in order to assess the 
      current place in therapy and future prospects of teneligliptin. Reported evidence 
      suggests that teneligliptin has consistent pharmacokinetic in mild, moderate, 
      severe or ESRD, without any need for dose adjustments. Limited data from small 
      sample studies of teneligliptin in DKD patients reported significant improvements 
      in glycaemic parameters. Additionally, there is an improvement in kidney 
      parameters like glycated albumin, urinary albumin and eGFR. There is an evidence 
      of reduction in biomarkers of kidney impairment like P-selectin (sP-selectin), 
      Platelet-Derived Microparticles (PDMPs) and Plasminogen Activator Inhibitor 1 
      (PAI-1). Clinical significance of these will be known in near future. Thus, 
      teneligliptin has an important place of therapy in the management of T2DM with 
      renal impairment.
FAU - Abubaker, Mohammed
AU  - Abubaker M
AD  - Professor, Department of Medicine, Deccan College of Medical Sciences , 
      Hyderabad, Telangana, India .
FAU - Mishra, Preetesh
AU  - Mishra P
AD  - Assistant Manager, Medical Services, Unichem Laboratories Ltd. , Mumbai, 
      Maharashtra, India .
FAU - Swami, Onkar C
AU  - Swami OC
AD  - Head of Medical Services, Unichem Laboratories Ltd. , Mumbai, Maharashtra, India 
      .
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20170101
PL  - India
TA  - J Clin Diagn Res
JT  - Journal of clinical and diagnostic research : JCDR
JID - 101488993
PMC - PMC5324442
OTO - NOTNLM
OT  - Diabetes mellitus
OT  - Dipeptidyl peptidase-4 inhibitor
OT  - Renal impairment
EDAT- 2017/03/10 06:00
MHDA- 2017/03/10 06:01
PMCR- 2017/01/01
CRDT- 2017/03/10 06:00
PHST- 2016/10/26 00:00 [received]
PHST- 2016/12/05 00:00 [accepted]
PHST- 2017/03/10 06:00 [entrez]
PHST- 2017/03/10 06:00 [pubmed]
PHST- 2017/03/10 06:01 [medline]
PHST- 2017/01/01 00:00 [pmc-release]
AID - 10.7860/JCDR/2017/25060.9228 [doi]
PST - ppublish
SO  - J Clin Diagn Res. 2017 Jan;11(1):OE05-OE09. doi: 10.7860/JCDR/2017/25060.9228. 
      Epub 2017 Jan 1.